New combo therapy aims to delay ovarian cancer return

NCT ID NCT04742075

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a combination of three drugs—olaparib, durvalumab, and a cancer vaccine called UV1—can help keep ovarian cancer from coming back after chemotherapy. The study includes 188 patients with recurrent ovarian cancer who do not have BRCA mutations. Participants are randomly assigned to receive either the triple combination or standard treatment to see which works better at delaying cancer progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
olaparib, durvalumab, and UV1 vaccine
What this could lead to
If successful, this could offer a new maintenance treatment option to delay cancer progression in patients with recurrent ovarian cancer who do not have BRCA mutations.
What could go wrong
This is an early phase 2 trial with a small number of participants, so results may not confirm benefit. The combination therapy may cause significant side effects and may not improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Rigshospitalet

    København Ø, Region Sjælland, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.